EQRx, Inc. – NASDAQ:EQRX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
EQRx stock price monthly change
+5.41%
month
EQRx stock price quarterly change
+4.46%
quarter
EQRx stock price yearly change
-57.91%
year
EQRx key metrics
Market Cap | 1.14B |
Enterprise value | 384.13M |
P/E | -5.23 |
EV/Sales | N/A |
EV/EBITDA | -2.68 |
Price/Sales | N/A |
Price/Book | 0.62 |
PEG ratio | 0.32 |
EPS | -0.16 |
Revenue | N/A |
EBITDA | -290.06M |
Income | -83.79M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEQRx stock price history
EQRx stock forecast
EQRx financial statements
| Dec 2022 | 0 | 135.09M | |
|---|---|---|---|
| Mar 2023 | 0 | -63.30M | |
| Jun 2023 | 0 | -72.95M | |
| Sep 2023 | 0 | -82.63M |
| 2025 | 2.60M | -284.57M | -10915.9% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-02-23 | -0.19 | -0.05 |
|---|---|---|
| 2023-05-08 | -0.12 | -0.17 |
| 2023-08-08 | -0.11 | -0.15 |
| 2023-11-09 | -0.16 | -0.18 |
| Dec 2022 | 1455016000 | 66.15M | 4.55% |
|---|---|---|---|
| Mar 2023 | 1383955000 | 69.64M | 5.03% |
| Jun 2023 | 1311398000 | 63.08M | 4.81% |
| Sep 2023 | 1240290000 | 69.37M | 5.59% |
| Dec 2022 | -105.79M | -398.41M | 327 |
|---|---|---|---|
| Mar 2023 | -85.54M | -40.35M | 127K |
| Jun 2023 | -76.89M | -44.04M | 74K |
| Sep 2023 | -61.90M | 129.87M | 209K |
EQRx alternative data
| Aug 2023 | 362 |
|---|---|
| Sep 2023 | 362 |
| Oct 2023 | 362 |
| Nov 2023 | 362 |
| Dec 2023 | 362 |
| Jan 2024 | 362 |
| Feb 2024 | 362 |
| Mar 2024 | 362 |
| Apr 2024 | 362 |
| May 2024 | 362 |
| Jun 2024 | 362 |
| Jul 2024 | 362 |
EQRx other data
27.94%
-47.06%
of EQRX is owned by hedge funds
67
-41
132.49M
-224.14M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|
| Quarter | Transcript |
|---|---|
| Q1 2023 8 May 2023 | Q1 2023 Earnings Call Transcript |
| Q3 2022 13 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 13 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 13 May 2022 | Q1 2022 Earnings Call Transcript |
-
When is EQRx's next earnings date?
Unfortunately, EQRx's (EQRX) next earnings date is currently unknown.
-
Does EQRx pay dividends?
No, EQRx does not pay dividends.
-
How much money does EQRx make?
EQRx has a market capitalization of 1.14B. EQRx earned 205.49M US dollars in net income (profit) last year or -$0.18 on an earnings per share basis.
-
What is EQRx's stock symbol?
EQRx, Inc. is traded on the NASDAQ under the ticker symbol "EQRX".
-
What is EQRx's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of EQRx?
Shares of EQRx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does EQRx have?
As Jul 2024, EQRx employs 362 workers.
-
When EQRx went public?
EQRx, Inc. is publicly traded company for more then 4 years since IPO on 3 Jun 2021.
-
What is EQRx's official website?
The official website for EQRx is eqrx.com.
-
Where are EQRx's headquarters?
EQRx is headquartered at 50 Hampshire Street, Cambridge, MA.
-
How can i contact EQRx?
EQRx's mailing address is 50 Hampshire Street, Cambridge, MA and company can be reached via phone at +61 73152255.
EQRx company profile:
EQRx, Inc.
eqrx.comExchange:
NASDAQ
Full time employees:
362
Industry:
Biotechnology
Sector:
Healthcare
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
50 Hampshire Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001843762
ISIN: US26886C1071
CUSIP: 26886C107
